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EpigeneticsWedeveloped a novel approach, J-binding protein 1 sequencing (JBP1-seq), that combines the beneﬁts of an im-
proved recombinant JBP1protein, Nextera-based library construction, and next-generation sequencing (NGS) for
genome-wide proﬁling of 5-hydroxymethylcytosine (5hmC). Compared with the original JBP1, this new recom-
binant JBP1was biotinylated in vivo and conjugated tomagnetic beads via biotin–streptavidin interactions. These
modiﬁcations allowed amore efﬁcient and consistent pull-downofβ-glucosyl-5-hydroxymethylcytosine (β-glu-
5hmC), and sequence-ready libraries can be generated within 4.5 h from DNA inputs as low as 50 ng. 5hmC en-
richment of human brain DNA using the new JBP1 resulted in over 25,000 peaks called, which is signiﬁcantly
higher than the 4003 peaks enriched using the old JBP1. Comparison of the technical duplicates and validations
with other platforms indicated the results are reproducible and reliable. Thus, JBP1-seq provides a fast, efﬁcient,
and cost-effective method for accurate 5hmC genome-wide proﬁling.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
The recent discovery that 5-methylcytosine (5mC) can be oxidized
into 5-hydroxymethylcytosine (5hmC) by the ten-eleven translocation
(TET) proteins added a new dimension to the mechanism and role of
DNA methylation in epigenetics [1,2]. In mammals, the brain had the
highest level of 5hmC compared to other tissues (see also the reviews
byWen and Tang and by Hajkova and colleagues, this issue). However,
the nature of 5hmC, compared with classical 5mC, remains unclear [3].
A previous study had found various differentially hydroxymethylated
regions between the human brain of adults and fetus (see review by
Hahn and colleagues, this issue) [4]. These dynamic changes andmolec-
ular functions of 5hmCare likely to contribute to the versatile epigenetic
mechanisms that mediate brain development and functional mainte-
nance of the adult brain.
Bisulﬁte sequencing (BS-seq) has beenused extensively tomapmeth-
ylation patterns in genomic DNA. In BS-seq, treatment of DNA with sodi-
um bisulﬁte converts unmodiﬁed cytosines to uracils, which are
subsequently read as thymines during sequencing. However, BS-seq
alone cannot distinguish 5hmC from5mCbecause both are resistant to bi-
sulﬁte conversion and are sequenced as cytosines. To resolve the issue,
two new techniques were developed, TET-assisted BS-sequencing (TAB-
seq) and oxidative bisulﬁte sequencing (oxBS-seq) [5,6]. TAB-seq utilizes
T4 phage β-glucosyltransferase (T4-βGT) to glucosylate 5hmC, which is
then protected from oxidation by the TET1 enzyme while 5mCs areung@zymoresearch.com
moresearch.com (X. Sun),ultimately oxidized to 5-fromylcytosine (5-fC) or 5-carboxylcytosine (5-
caC). The resulting 5-fCs or 5-caCs are readily converted into uracils dur-
ing bisulﬁte conversion, and, therefore, all the remaining cytosines after
sequencing are the footprints of 5hmCs. Another method, oxBS-seq, dis-
criminates between 5mC and 5hmC by using a highly selective chemical
oxidant, potassium perruthenate (KRuO4), to convert 5hmC to 5-fC,
which is then converted to uracil during bisulﬁte treatment. In contrast,
5mC is resistant to KRuO4 oxidation and, thus, remains as a cytosine
after bisulﬁte sequencing. Identiﬁcation of 5hmC is achieved by compar-
ing the results from oxBS-seq and regular BS-seq. Although both TAB-
seq and oxBS-seq provide single-base resolution of 5hmC, the sequencing
cost required to provide sufﬁcient depth for accurately determining low
levels of 5hmC prohibits them from wide applications. Thus far, several
groups developed afﬁnity-based methods to enrich for 5hmC.
Hydroxymethylated DNA immunoprecipitation (hMeDIP), similar to the
established methylated DNA immunoprecipitation (MeDIP), utilizes
monoclonal or polyclonal antibodies to immunoprecipitate 5hmC or
modiﬁed 5hmC [7]. Other methods require glucosylation of 5hmC by
T4-βGT with modiﬁed glucose substrates, which can be enriched by a
speciﬁc protein (e.g. JBP1) or can be chemically modiﬁed further with bi-
otin labeling, resulting in efﬁcient pull-downusing biotin–streptavidin in-
teractions (e.g. hMeSeal and GLIB method) [8–11]. However, each of
these methods has its shortcomings: hMeDIP, like other antibody based
methods, had been reported to have bias toward some speciﬁc sequences
and modiﬁcation dense region, while the hMeSeal and GLIB methods re-
quire additional chemical modiﬁcations that can damage DNA and intro-
duce higher background [12]. J-binding protein 1 (JBP1)-based methods,
although simple and straightforward, had relatively lower levels of en-
richment when compared with the hMeSeal and GLIB methods [12]. In
addition, all the enrichment methods require high genomic DNA input,
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the investigations of precious samples, such as stem cells or selectively
isolated cellular subpopulations (i.e. diverse neuronal cells from a whole
brain sample).
Here, we describe an improved version of JBP1 protein that allows a
fast and efﬁcient enrichment of 5hmC. The original JBP1 proteins were
chemically conjugated to epoxy-activated magnetic beads via epoxy-
amine reaction. This new recombinant JBP1 was expressed from a
gene construct that added both His tag and Avi tag to the protein,
allowing biotinylation of the protein in vivo. After protein puriﬁcation,
the biotinylated JBP1 was conjugated to streptavidin-coated magnetic
beads. Compared with the original JBP1, the new version of JBP1 mag-
netic beads allowed more efﬁcient and consistent pull down of β-
glucosyl-5-hydroxymethylcytosine (β-glu-5hmC). By incorporating
the commercial Nextera DNApreparation kit, we have developed a pro-
tocol known as JBP1-seq that can be completed within 4.5 h and allows
for genome-wide 5hmC detection from DNA inputs as low as 50 ng.
Thus, JBP1-seq provides a fast, efﬁcient, and cost-effective method for
accurate genome-wide proﬁling of 5hmC.2. Results
2.1. Production of an improved JBP1-coated magnetic bead
Base J (β-D-glucosyl-hydroxymethyluracil) was discovered in the
genome of certain pathogenic Trypanosoma and Leishmania but is ab-
sent from other eukaryotes. JBP1 proteins, isolated from Crithidia
fasciculata or other recombinant resources, bind speciﬁcally to both J-
DNA and β-glu-5hmCDNAwith high afﬁnity, which has been exploited
for the enrichment of 5hmC containing DNA [8,9]. The full length JBP1
protein isolated from C. fasciculata is a 93 kDa protein that contains
160 amino acid J-DNA binding domains responsible for binding of β-
glu-5hmC. In the original JBP1 magnetic beads that were used for
5hmC enrichment, puriﬁed recombinant JBP1 proteins were chemically
conjugated to glycidyl ether (epoxy)-functionalized magnetic beads via
epoxy-primary amine reactions [8,9]. However, chemically conjugated
JBP1 had been shown to have inconsistent and less efﬁcient 5hmC
pull-downs compared to hMeSeal and hMeDIP [9,12]. We reasoned
that the JBP1 protein crosslinked to the beads in a random orientation,
which may affect the DNA binding properties of JBP1 and lead to inefﬁ-
cient pull downs of β-glu-5hmC. To address the issue, we expressed a
new recombinant full length JBP1 of C. fasciculata in which a tandem
(His)6 and Avi tag peptide was fused at the N-terminal end. The JBP1Fig. 1. The new JBP1 magnetic beads speciﬁcally enriched DNA that contains β-glu-5hmC. (A) M
9:1, respectively. Both plasmids have identical sequence except that the methylated plasmid h
50 ng of human brain genomic DNA spiked with 1 ng of 5mC/5hmC plasmid control was per
using primers ﬂanking the restriction enzyme site of the methylated and hydroxymethylated p
ments, indicating that the enrichmentwas speciﬁc to 5hmC.M: 100 bpDNA ladder (ZymoResea
DNA with 5mC/5hmC plasmid control).fusion protein can be biotinylated in vivo, puriﬁed by Ni-NTA afﬁnity
chromatography, and linked to streptavidin magnetic beads through
high afﬁnity biotin–streptavidin interactions in a deﬁned orientation.
2.2. Selective pull-down of β-glu-5hmC
To conﬁrm that the JBP1-coated magnetic beads could speciﬁcally
pull-down glucosylated 5hmC, we performed a JBP1 pull-down assay
using human brain genomic DNA spiked with a control, which
contained 5mC and 5hmC plasmid DNA at a molar ratio of 9:1. Both
plasmids had identical sequences except that a BamHI restriction site
in the 5mC plasmid was replaced with a KpnI restriction site in the
5hmC plasmid (Supplementary ﬁle 1). The 5mC plasmid had methylat-
ed cytosines in the CpG context while the 5hmC plasmid had
hydroxymethylated cytosines in the CpG context. Enrichment can be
evaluated by amplifying a 400 bp product from any sample “spiked”
with the 5mC/5hmC plasmid control using primers that ﬂank the re-
striction sites, allowing unbiased ampliﬁcation of either plasmid
(Fig. 1A). The amplicon can be digested with KpnI, and successful en-
richment of 5hmC is based on KpnI cleavage of the amplicon to
200 bp fragments. Six human brain genomic DNA spiked with the
5mC/5hmC plasmid control were enriched and ampliﬁed with
control-speciﬁc primers. A 400 bp product was successfully ampliﬁed
and digestion with KpnI resulted in 200 bp fragments (Fig. 1B, lanes
1–6). An input control that was not enriched resulted in a 400 bp
amplicon that was resistant to KpnI digestion (Fig. 1B, lane Ctl). This
PCR analysis showed that the JBP1-coated magnetic bead preferentially
pulled downDNA that containedβ-glu-5hmCwhile having little afﬁnity
for the 5mC DNA substrates.
2.3. Genome-wide 5hmC proﬁling of human brain DNA by JBP1-seq
We streamlined the library preparation of new JBP1-enriched librar-
ies by integrating it with the Illumina Nextera DNA sample prep kit. The
workﬂow of JBP1-seq, shown in Fig. 2, involved four main steps: (1)
tagmentation of genomic DNA, (2) glucosylation of 5hmC using β-GT,
(3) JBP1-magnetic bead (JBP1-MB) pull-down, and (4) PCR ampliﬁca-
tion. The Nextera technique utilizes an engineered transposons, which
allows simultaneous fragmentation of the genomic DNA and the addi-
tion of sequencing-compatible adapter sequences. Tagmented libraries
can be ampliﬁed with adapter-speciﬁc, indexing primers (denoted as
Read 1 and Read 2 sequencing primers) to barcode different samples
and allow sequencing on any Illumina systems. Using this protocol, weethylated DNA plasmids were mixed with hydroxymethylated DNA plasmids at a ratio of
ad a BamH1 site and the hydroxymethylated plasmid had a Kpn1 site. An enrichment of
formed with the new JBP1 magnetic beads. (B) The enriched DNA was ampliﬁed by PCR
lasmid. The resulting amplicon (400 bp) was digested with KpnI, resulting in 200 bp frag-
rch); 1–6: test samples; B: non-coatedmagnetic beads control; Ctl: input control (genomic
1.  Tagmentation of  genomic DNA
(15 mins) 
2. Glycosylation of 5-hmC by T4-ßGT
(65 mins)
3. JBP1-MB Pull down
(90 mins) 
4. PCR Amplification
(60 mins) 
5-mC   5-hmC     C      Glucose   JBP1-MB  
Fig. 2. The four main steps of the JBP1-seq workﬂow. (1) Genomic DNA was ﬁrst tagmented by utilizing transposons to simultaneously fragment DNA and add adapter sequences.
(2) 5hmC sites are glucosylated by T4-βGT. (3) JBP1-magnetic beads (JBP1-MB) were used to selectively enrich for fragments containing β-glu-5hmC. (4) The enriched library was am-
pliﬁed with Read 1 and Read 2 sequencing primers to add on the P5 and P7 adapter sequences, respectively. These are necessary to make the libraries compatible with next-generation
sequencing. Read 1 and Read 2 primers also contain an 8 base indexes, denoted as Index 1 and Index 2, respectively, to barcode and identify unique samples.
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for human brain genomic DNA and sequenced the libraries on the
Illumina HiSeq using 50 bp single-end reads.
A total of 12 and 15million readswere generated for JBP1-seq-1 and
2, respectively, and both had approximately 94% of the reads mapped
uniquely to the reference human genome (Table 1). A library enriched
using the old JBP1 (JBP1-seq-old) was also prepared, and 98% of the ap-
proximately 36 million reads had aligned. Peak calling usingMACS pro-
gram identiﬁed 25,605 and 32,096 peaks, which is signiﬁcantly higher
than the 4003 peaks from the library enriched from the original JBP1
protein [13]. The increase in peaks called by the new JBP1-seq allowed
a greater coverage of CpGs in the genome, indicating a more efﬁcient
pull-down of β-glu-5hmC by the new JBP1-coated magnetic beads.
JBP1-seq-old had nearly twice as many reads as JBP1-seq-1 and 2 but
only 1.24% of the reads fell within peaks while JBP1-seq-1 and 2 had
over 10% of the reads in peaks (Table 1). This indicated that the new
JBP1-seq had less background compared to JBP1-seq-old. The other
reads that did not fall within peaks could have also resulted from the
low hydroxymethylation levels at the region, and as a result of the
weaker signal, the peaks were not called by MACS. We also found that
the average fold enrichment across all peaks in JBP1-seq-1 and JBP1-
seq-2 was 7.59 and 7.54, respectively, which was lower than the 27.97
average fold enrichment of JBP1-seq-old. Also, the average peak width
of the new JBP1-seq is broader than the that of the old JBP1-seqTable 1
Sequencing results of the new and old JBP1-seq. The percentage of the genome and total CpG
peaks. SE: single-end reads.
Sample Sequencing
parameters
Total #
of reads
Mapped
reads
% of Reads
in peaks
# P
fro
JBP1-seq-1 50 bp SE 12,529,612 11,859,885 10.49% 25
JBP1-seq-2 50 bp SE 15,294,151 14,434,491 11.07% 32
JBP1-seq-old 36 bp SE 36,269,633 35,585,099 1.24% 4(Fig. 3). We reasoned that the higher fold enrichment for the old JBP1-
seq is due to its bias toward the capture of highly hydroxymethylated
regions (Fig. 3A). The new JBP1-seqwas also more efﬁcient at capturing
less hydroxymethylated sites and therefore lowering the overall fold
enrichment. In addition, the broader peaks observed for JBP1-seq-1
and 2 could have resulted from the increased enrichment of adjacent
hydroxymethylated sites (Fig. 3B). Nevertheless, both the old and new
JBP1-seq had similar enrichment patterns across the genome (Fig. 4A).
Further analysis of three peak regions spanning 1361, 2328, and 767
base pairs within chr9, chr11, and chr4, which had high, low ormedium
enrichment respectively, showed that the three libraries had similar en-
richment trends (Fig. 4B). In summary, these data suggested that the
new JBP1-magnetic beads had a higher 5hmC enrichment efﬁciency
that allowed recovery of the previously undetected 5hmC sites.
The previous studies had shown that the majority of
hydroxymethylation was enriched in genic regions, so we next exam-
ined 5hmC across the entire genome [10]. Again, we found that there
was a dramatic loss of 5hmC in transcription start sites (TSS) and tran-
scription termination sites (TTS) while the level of 5hmC was elevated
in the gene body (Fig. 4C). In addition, it is worth noting that chromo-
somes 16, 17, 19 and 22 had relatively higher density of enriched
peaks in respect to their chromosome size (Supplementary Fig. 1). In-
terestingly, this pattern was in good agreement with another study
that mapped 5hmC in human brain DNA [15].sites covered was calculated using the number of bases or CpGs, respectively, covered by
eaks
m MACS
# of Bases
covered by peaks
Genomic
coverage %
CpGs in
peaks
% of Total
genomic CpGs
,605 38,237,329 1% 1,180,721 4%
,096 40,049,152 1% 1,268,057 4%
003 408,148 0.01% 7654 0.03%
Fig. 3. Comparison of the old and new JBP1 enrichments. Box plots show the average (A) fold enrichment and (B) peak width for all the peaks identiﬁed from the old JBP1-seq and new
JBP1-seq. The whisker lines are 1.5*IQR (inner quantile range).
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To conﬁrm that the peaks discovered in the new JBP1-seq were not
due to random non-speciﬁc interactions but were true 5hmC sites, we
ﬁrst compared the two technical replicates of the JBP1-seq to determine
how many peaks were repeatedly called in both cases. Although peakJBP1-Seq-old
A
B C
Fig. 4.Genomic distribution of JBP1 enrichments. (A) JBP1-seq-old, JBP1-seq-1, and JBP1-seq-2 h
prepared using the old JBP1, and JBP1-seq-1 and JBP1-seq-2 librarieswere prepared using thene
JBP1-seq-old, JBP1-seq-1 and JBP1-seq-2. Region 1: chr9: 44,070, 133–44,071,494; region 2: ch
enrichment of TSS, gene body, and TTS.callings in a ChIP-seq sample are well established, methods for compar-
ing two ChIP-seq samples are not. Merely comparing two samples by
overlapping the genomic coordinates of their respectively called peaks
has inherent statistical problems and leads to an underestimation of
their similarity [16]. To address that, Bardet et al. developed a computa-
tional pipeline for comparative ChIP-seq analyses [16]. Using thatJBP1-Seq-1
ave similar genomic distribution of the 5-hmC enrichment peaks. JBP1-seq-old librarywas
w recombinant JBP1. (B) Fold enrichment comparison for three different peak regions from
r11: 964,390–966,718; region 3: chr4: 159,103,768–159,104,535. (C) The average 5-hmC
372 L. Cui et al. / Genomics 104 (2014) 368–375protocol, we analyzed the two JBP1-seq samples and found that there
were over 95% overlapping between the technical replicates. In addi-
tion, we also analyzed the data using paired sample mode in MACS by
inputting one sample as a control. Only 300 unique peaks were called
from the comparison between JBP1-seq-1 and JBP1-seq-2, which is
less than 1% of the total peaks called from each sample individually, in-
dicating the JBP1-seq libraries were very reproducible, as can be seen
from the comparison of the different proﬁles (Fig. 5).
To further validate JBP1-seq-enriched region, we then cross checked
the two new JBP1-seq data with Reduced Representation
Hydroxymethylation Proﬁling (RRHP) data. RRHP is an enzyme-based
method which maps 5hmC sites by exploiting the use of β-glucosyl
transferase to inhibit enzymatic digestion at the junction where
adapters are ligated to a genomic library [17]. Therefore, only library
fragments presenting glucosylated 5hmC residues at the junction will
be sequenced; higher read counts in RRHP are an indication of higher
5hmC levels. RRHP can detect sites with low 5hmC abundance, but the
assay is restricted to enzyme cutting sites. In principal, all the 5hmC
sites detected by RRHP should be covered by JBP1-seq. We found a
large number of 5hmC sites that were covered by the enrichment
peaks from JBP1-seq (Fig. 5). Approximately 35% and 32% peaks of
JBP1-1 and JBP1-2 were covered by RRHP. We further validated two
loci in Chr3 and Chr17 that were detected by the two new JBP1-seq
and RRHP but not JBP1-seq-old (Figs. 6A and B). For locus 2 in Chr17,
there were some reads detected for JBP1-seq-old, but they were rela-
tively low and not identiﬁed as peaks. These reads were likely called
due to the fact that the new JBP1-seq had a lower background level
compared to JBP1-seq-old, and this lower thresholdwas used to analyze
JBP1-seq-old aswell. The two lociwere validated using quantitative PCR
and glucosyl-sensitive restriction enzyme digestion (gRES-qPCR)
(Figs. 6A and C). First, samples were treated or mock-treated with β-
GT and, then, digested with MspI. Following puriﬁcation, the loci were
ampliﬁed to determine resistance to MspI restriction conferred by
glucosylation of the 5hmC position. The ampliﬁcation proﬁles of the
treated (digested +) and mock-treated (digested −) samples were
compared to untreated and undigested genomic DNA (intact). Digested
+ samples with a CT closer to the intact sample indicated higher
hydroxymethylation levels while a CT more similar to the digested−Fig. 5.UCSC genome browser track comparing the enrichment peaks of JBP1-seq-old, JBP1-seq-
are indicated by the lines.sample indicated less hydroxymethylation. For the two loci, we found
that the treated sample (digested +) had an ampliﬁcation curve more
similar to the positive control (intact), indicating both loci had a high
level of hydroxymethylation (Figs. 6B and D). Again, the results are con-
sistent among the threemethods, indicating JBP1 is a robustmethod for
5hmC detection.
3. Discussion
Since it was discovered as an important epigenetic marker in 2009,
studies on 5hmC have increased dramatically over the last several
years, but the molecular functions of 5hmC still remain unclear. The in-
crease in 5hmC research has been largely driven by the development of
numerous new technologies for genome-widemapping of 5hmC. Based
on the method utilized for detecting 5hmC, the technologies were clas-
siﬁed into three main categories:(1) bisulﬁte sequencing-based
methods, like TAB-seq and OxBS-seq,(2) enzyme-based methods like
RRHP, HELP-GT assay, and HMST-seq, and (3) enrichment-based
methods, like hMeDIP, hMeSeal, and the GLIB method [17–19]. Al-
though TAB-seq and oxBS-seq are more attractive considering they
can detect 5hmC at single-base resolution and in a quantitativemanner,
the requirement for high DNA input and higher sequencing depth has
prohibited them from being practical methods for a large-scaled cohort
study. In contrast, the enzyme-based methods, although relatively
straightforward, rely on restriction enzymes and, therefore, are limited
in detection capacity and can result in an absence of information on crit-
ical 5hmC sites. Given this, enrichment-based methods are appropriate
tools to balance cost and detection capacity. However, most of the cur-
rent enrichment-based methods still have some drawbacks or inherent
bias. To address that, we presented a simple and fast method for
genome-wide 5hmC detection based on a new recombinant JBP1 pro-
tein.We streamlined the JBP1-seq library prep by integrating the highly
efﬁcient JBP1 pull-down into Nextera DNA sample preparation kit. This
not only shortened the entireworkﬂow to 4.5 h but also lowered the ini-
tial DNA input down to 50 ng, making it more applicable to precious
clinical samples. We attempted to perform gene ontology analysis by
GREAT for the enriched regions identiﬁed by the new JBP1-seq but
were unable to identify any speciﬁc pathways or functions that may1, and JBP1-seq-2 to RRHP in chr7: 7,510,000–7,670,000. The 5hmC sites detected by RRHP
Locus 2 (chr17:7259614 - 7259808)  gRES-qPCR amplicon size: 195bp (indicated by pink bar)
Locus 1 (chr3:47865078 - 47865228)  gRES-qPCR amplicon size: 151bp (indicated by pink bar)
A B
C D
Fig. 6. Validating 5hmC sites from the JBP1-seq by RRHP and gRES-qPCR.(A) and (C) Genome browser track shows enrichment peaks of JB1-seq-old, JBP1-seq-1, and JBP1-seq-2 with the
read counts from the RRHP assay. Higher read counts in RRHP are an indication of higher 5hmC levels. (B) and (D) Two 5hmC sites identiﬁed by both the new JBP1-seq and RRHP were
validated by gRES-qPCR. The loci validated (indicated by the pink bar) were located in chromosomes 3 and 17; the 5hmC siteswere found to have 129 and 87 reads in RRHP, respectively.
Treated sample: digested +; mock-treated sample: digested−; untreated sample: intact.
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Future identiﬁcation of 5hmC sites with housekeeping characteristics
would be important for characterizing different tissues or cancers or
serve as a positive control for assays involving hydroxymethylation.
This new JBP1-seq allowed greater enrichment of hydroxymethylated
regions compared to the old JBP1, and the peaks were able to cover more
CpG sites, which is important since most hydroxymethylation are in the
CpG context, especially in the human brain [20]. However, as with any
other enrichment methods, it is important to determine if this new JBP1
has any preferential binding sites or other biases. This is worth observing
in future studies involving a larger sample pool or samples with various
hydroxymethylation levels. However, our comparison between the tech-
nical replicates and validation with other platforms indicated that the re-
sults are reproducible and reliable. In summary, this new JBP1-seq
provides a powerful tool to further research of 5hmC at a genome-wide
scale.
4. Materials and methods
4.1. Recombinant J-binding protein 1 expression and puriﬁcation
The gene coding for J-binding protein 1 (JBP1) from C. fasciculata
was synthesized by GeneArt (Germany). After synthesis, the gene was
cloned into pET27-His-Sumo-Avi tag. Cultures of XJb (DE3) harboring
pET27-His-Sumo-JBP1 and pBirA encoding biotin ligase were grown in
100 mL of Zymo Expansion media (Zymo Research) at 37 °C to an OD
A600 of 0.6. Then, 500 mL of overexpression medium (Zymo Research)
supplemented with 20 mM of D-biotin, 35 mg/mL of kanamycin, and15 mg/mL of chloroamphenicol was added to the culture, and the incu-
bation temperature was reduced to 18 °C for 16 h. IPTGwas added into
the medium at 0.5 mM, and the culture incubated at 18 °C for an addi-
tional 4h. The cells were harvested by centrifugation and suspended in
10 mL His-binding buffer (500 mM of NaCl, 25 mM of Tris–HCl pH 7.5,
5 mM of imidazole, 10% (v/v) glycerol), and the cells were then
freeze-thawed at−80 °C and room temperature for 3 cycles. The lysate
viscosity was reduced by sonication on ice. The lysate was cleared by
centrifugation for 10 min at 20,000 ×g, and the supernatant was
mixed with 2 mL of Zymo His-binding resin equilibrated in His-
binding buffer for 1 h. Themixturewas applied to a column andwashed
with His-binding buffer until the ﬂow through had anODA280 of 0. JBP1
was eluted with 20 mL of His-binding buffer supplemented with
500 mM of imidazole. Fractions containing the highest concentration
of protein were pooled and stored at−80 °C.4.2. Coupling JBP1 to magnetic beads
Five milligrams of DynabeadsMyOneStrepavidin C1magnetic beads
(Invitrogen) was equilibrated according to manufacturer's instructions
and suspended in 500 μL of JBP1 binding buffer (10 mM of Tris–HCl,
150 mM of Nacl, 2 mM of EDTA, 10% glycerol, 0.05% Tween-20,
pH 8.0). About 200 μg of JBP1 protein in JBP1 binding buffer was
added to the beads, and the bead and JBP1 solution rotated slowly at
4 °C for 24 h. After incubation, the beads were washed three times
with 1 mL of JBP1 binding buffer to remove unbound proteins. The
beads were then suspended in 500 μL of JBP1 binding buffer. Beads
374 L. Cui et al. / Genomics 104 (2014) 368–375were prepared freshly for each experiment as it was found that several
freeze-thaw cycles dramatically reduce binding capacity.4.3. JBP1-seq library preparation and sequencing
The tagmentation DNA enzyme from the Nextera DNA sample prep-
aration kit (Illumina) was used to fragment and add adapter tags to
50 ng of human brain genomic DNA (Zymo Research Cat.# D5018).
After tagmentation, DNA was puriﬁed using DNA Clean &
Concentrator-5 Kit (Zymo Research). The puriﬁed DNAwas then spiked
with 5mC/5hmC plasmid control (sequence in Supplementary ﬁle 1) as
previously described in the text and subjected to glucosylation in a 50 μL
of reaction containing 4 units (U) β-GT and 20 μM UDP-glucose in a β-
GT reaction buffer at 37 °C for 1 h followed by heat-inactivation at
65 °C for 15 min (Zymo Research). After incubation, 50 μg of JBP1-
coatedmagnetic beads and 500 μL of JBP1 binding bufferwere added di-
rectly to the glucosylation reaction. The suspension rotated gently at
room temperature for 60 min. Beads were washed three times with
1 mL of JBP1 binding buffer to remove unbound DNA, and then the
enriched DNA was collected by suspending the beads in 20 μL of DNA
elution buffer (Zymo Research). To monitor 5hmC enrichment efﬁcien-
cy, a 2 μL aliquot of the enriched DNA was ampliﬁed with primers spe-
ciﬁc to the 5mC/5hmC plasmid control (Fwd: 5′ CGCCACCAAACGTTTC
GGCGA; Rev: 5′TGGAGTGGTGAATCCGTTAGCG). The amplicon was
then digested with 20 U of KpnI at 37 °C for 1 h and visualized on a
1.4% (w/v) agarose gel; a successful enrichment would result in
200 bp of fragments. The enriched DNA was then subjected to limited
ampliﬁcation following manufacturer's protocol in the Nextera DNA
preparation kit (Illumina). The ampliﬁed library was then puriﬁed
using the DNA clean & concentrator kit, and indexed libraries were
multiplexed using equal molarity and quantiﬁed by qPCR. The JBP1-
seq libraries were sequenced following Illumina standard protocol on
HiSeq 1500 with 50 bp single-end reads.
The library prepared using the old JBP1-coated magnetic beads was
ﬁrst processed by fragmenting human brain genomic DNA (Zymo Re-
search Cat# D5018) with 1 U of dsDNA Shearase Plus (Zymo Research).
Enrichment was done following the same procedures as above for the
glucosylation and enrichment but the old JBP1-coated magnetic beads
were used. A library was prepared from the enriched 5hmC DNA by
end-blunting the fragments with Klenowfragment (3′- N 5′exo) (NEB)
and T4 DNA polymerase (NEB) followed by A-tailing using Klenow frag-
ment (3′- N 5′ exo). Illumina TruSeq P5 and P7 adapters with a thymine
overhangwere ligated to theDNA fragments using T4DNALigase (NEB)
by incubating the reaction at 16 °C for 12 h. The adapterized library was
then ampliﬁedwith primers speciﬁc to the P5 and P7 adapters using the
following thermal proﬁle: denaturation of 95 °C for 30 s followed by
15 cycles of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s. The library
was sequenced on the Genome Analyzer IIx (Illumina) with 36 bp
single-end reads.4.4. Sequence alignment and bioinformatics analysis
FASTQ sequencing ﬁles from each library were aligned to the
human reference genome (GRCh37/hg19) using Bowtie. The best
alignment and reporting option were used, which corresponded to
no more than 2 bp mismatches across the read. 5hmC peak calling
was performed using non-duplicate reads with MACS program. De-
fault parameters were used as follows: effective genome size =
2.70e + 0, band width = 300, model fold = 10, 30, tag size = 49
or 31, p value cutoff = 1.00e-05, range for calculating regional lamb-
da is: 10,000 bps. Gene ontology analysis for the enriched 5hmC
peaks was performed using the Genomic Regions Enrichment of An-
notations Tool (GREAT) and cis-regulatory element annotation sys-
tem (CEAS) [19].4.5. Validation by RRHP and gRES-qPCR
A RRHP library was generated previously. Human brain DNA
(200 ng) was fragmented with MspI (NEB) and puriﬁed with the DNA
clean and concentrator kit. Puriﬁed fragments were ligated to modiﬁed
Illumina P5 and P7 TruSeq adapters using T4 DNA ligase. The adapters
were designed so that when the P5 adapterwas ligated to the DNA frag-
ment, the CCGG site was reconstituted, but at the junctionwhere the P7
adapter was ligated, a TCGG site would result. The library was
glucosylated with T4 β-glucosyltransferase (Zymo Research) and then
subjected to a ﬁnal round ofMspI digestion to eliminate fragments lack-
ing glucosylation at the adapter junction. The libraries were size-
selected from 100 to 500 bp and then subjected to limited ampliﬁcation
with QuestTaq (Zymo Research) using indexing, adapter-speciﬁc
primers. Following puriﬁcation and quantiﬁcation, libraries were se-
quenced with 50-base paired-end reads on the HiSeq2000 platform
(Illumina). FASTQ data were ﬁltered for the CCGG tag and aligned to
hg19 with Bowtie.
gRES-qPCR was carried out using Quest 5hmC detection kit (Zymo
Research) to validate locus 1 (chr3: forward 5′-GTGGCTCTCGAGGGTG
GTACTGAC-3′ and reverse 5′-GGCAACGGAAGATGGCAGCCA-3′) and
locus 2 (chr17: forward 5′- CCTCATGCAGCAGGGAGAAT-3′ and reverse
5′- ATGGTCTCCCGAAGCACATC-3′). The same human brain DNA
(100 ng) was glucosylated with 10 U of β-GT (Zymo Research) and
100 nM of UDPG (Zymo Research) or mock-treated without enzyme
at 37 °C for 2 h. To the same reactions, 20 U of MspI (NEB) was added
and incubated for an additional 2 h. Following heat inactivation at
65 °C for 15 min, reactions were puriﬁed with the DNA clean and con-
centrator kit and quantiﬁed. 10 ng of each treatment groupwas utilized
for qPCR in triplicate with QuestTaq qPCR Master Mix (Zymo Research)
and 200 nM of primers (IDT). Reactions were ampliﬁed on a CFX96 cy-
cler (Bio-Rad) with the thermal proﬁle: 95 °C for 3 min, 40 cycles of
95 °C for 30 s, 60 °C for 20 s, 72 °C for 20 s, and then a ﬁnal extension
at 72 °C for 1 min before a 4 °C hold. All ampliﬁcations were then sub-
jected to melt curve analysis to ensure speciﬁc ampliﬁcation and
identity.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2014.08.023.
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